Impact & Population Health
Generate real-world evidence on the health impact of cancer interventions to inform policy change and implementation aligned with value-based cancer care in Singapore.
The Impact and Population Health platform measures the real-world health impact of cancer interventions in Singapore, generating evidence to inform national cancer policy and value-based care delivery.
STCC brings together expertise from across Singapore's healthcare ecosystem, including programmes under the Consortium for Clinical Research and Innovation, Singapore (CRIS), academic partners such as the Saw Swee Hock School of Public Health (opens in new tab), and Ministry of Health agencies, working towards a shared goal: improving cancer care quality while reducing its burden on patients and the healthcare system.
A core focus is the national coordination of evaluation studies for STCC Signature Programmes, including precision oncology initiatives and population-level cancer screening, ensuring these programmes are grounded in rigorous impact evidence
_AdobeStock_168306631.jpeg)
Generating Real-World Health Impact Evidence for Cancer Interventions
The Impact and Population Health platform aims to bridge clinical research and public health data to deliver insights across three core pillars:
Population Health
Understand how cancer and cancer interventions affect populations across Singapore.
The platform supports:
Cancer incidence and trend analyses
Survivorship and long-term outcomes research
Population-level evaluation of cancer interventions
Health equity and disparities research
Analysis of disease burden and patient outcomes
Health Economics
Understand the value, affordability and healthcare system impact of cancer interventions.
The platform supports:
Cost-effectiveness analysis
Real-world healthcare cost evaluation
Health technology assessment
Economic evaluation of cancer interventions
Evaluation of end-of-life care
Healthcare resource utilisation studies
Prevention & Preparedness
Generate evidence to strengthen cancer prevention, early detection and healthcare system readiness.
The platform supports:
Cancer prevention research
Screening and early-detection evaluation
Benchmarking and performance assessment
Long-term cancer outcome analysis
Healthcare system resilience and preparedness
How Researchers and Partners Can Work With Us
Researchers, healthcare institutions, public agencies and industry partners can work with the Impact & Population Health Platform to generate evidence across the cancer research and care pathway.
Evaluate Impact & Value
Understand real-world outcomes, healthcare utilisation, costs and cost-effectiveness.
Improve Population Cancer Outcomes
Study cancer trends and evaluate prevention, screening and early-detection strategies.
Translate Evidence into Practice & Policy
Support implementation, healthcare planning, policy development and resource allocation.
_AdobeStock_519678386.jpeg)
Turn Your Research Goals Into Collaborative Action
Connect with STCC to explore how our expertise and research ecosystem can support your research and partnership objectives.
STCC Research Spotlight
Presented · AACR Journals: Projecting the future cancer burden in Singapore: National incidence and direct medical cost estimates to 2050
STCC contributed to this abstract presented at Cancer Research (American Association for Cancer Research), projecting Singapore's future cancer burden. This work provides long-range epidemiological insights to guide national cancer planning and resource allocation. Cancer Research, Vol. 86, Supplement 7 · Abstract 3567 · AACR Journals
Presented · Journal of Clinical Oncology (2026 ASCO Annual Meeting): The cost of cancer care in Singapore: A population-based analysis of healthcare expenditures and survivorship.
Supported by the STCC Impact & Population Health platform, this abstract presented at the 2026 ASCO Annual Meeting, examining direct medical costs and survival outcomes across 15 common cancers in over 100,000 patients nationally. The study found that treatment costs have risen faster than survival gains for several cancer types, underscoring the need for value-based cancer policies. Journal of Clinical Oncology · Abstract e23397 · ASCO Meeting Abstracts
Presented · Journal of Clinical Oncology (2026 ASCO Breakthrough): Trends in gynaecological cancer incidence in Singapore over the last two decades
Supported by the STCC Impact & Population Health platform, this abstract presented at the 2026 ASCO Breakthrough Meeting, evaluating national incidence trends in cervical, ovarian, and uterine cancers over a 22-year period. The study identified a significant rise in uterine cancer incidence, particularly among younger women, alongside declining cervical cancer rates, demonstrating evolving cancer risks and informing future strategies for women's health and cancer control in Singapore. Journal of Clinical Oncology, Vol. 44, No. 19 Suppl · Abstract 217 · ASCO Breakthrough 2026.